Dabrafenib (GSK2118436)

Name: Dabrafenib (GSK2118436)
Brand: Selleck Chemicals
SKU: S2807
Rating: 5 (164 reviews)

For research use only.

Catalog No.S2807

164 publications

Dabrafenib (GSK2118436) Chemical Structure

CAS No. 1195765-45-7

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Selleck's Dabrafenib (GSK2118436) has been cited by 164 publications

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Nature, 2019, 575(7781):203-209

PubMed: 31666698 ( click the link to review the publication )

Nat Med, 2018, 24(2):203-212

PubMed: 29334371 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Cancer Discov, 2018, 8(4):417-427

PubMed: 29431697 ( click the link to review the publication )

Nature, 2017, 550(7674):133-136

PubMed: 28953887 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2016, 352(6282):189-96

PubMed: 27124452 ( click the link to review the publication )

Nat Med, 2016, 22(9):1056-61

PubMed: 27500726 ( click the link to review the publication )

Cancer Cell, 2016, 12;30(3):485-498

PubMed: 27523909 ( click the link to review the publication )

Cancer Discov, 2015, 5(4):358-67

PubMed: 25673644 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202004707

PubMed: 32561648 ( click the link to review the publication )

Oncogene, 2020, 39(20):4132-4154

PubMed: 32238882 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3205

PubMed: 33143299 ( click the link to review the publication )

Cancers (Basel), 2020, 22;12(2) pii: E512

PubMed: 32098410 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2020, 10.1111/pcmr.12932

PubMed: 33000894 ( click the link to review the publication )

Cell Death Dis, 2020, 11(11):973

PubMed: 33184267 ( click the link to review the publication )

Cell Commun Signal, 2020, 18(1):156

PubMed: 32967672 ( click the link to review the publication )

ACS Infect Dis, 2020, acsinfecdis.0c00486

PubMed: 33183004 ( click the link to review the publication )

Sci Rep, 2020, 8;10(1):7826

PubMed: 32385388 ( click the link to review the publication )

Sci Rep, 2020, 27;10(1):5557

PubMed: 32221312 ( click the link to review the publication )
J Biol Chem, 2020, 295(8):2407-2420

PubMed: 31929109 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 13

PubMed: 32404982 ( click the link to review the publication )

Front Chem, 2020, 23;8:184

PubMed: 32266211 ( click the link to review the publication )

Pathol Oncol Res, 2020, 10.1007/s12253-020-00834-y

PubMed: 32591993 ( click the link to review the publication )

Anticancer Res, 2020, 40(4):1867-1874

PubMed: 32234874 ( click the link to review the publication )

Br J Cancer, 2020, 122(6):789-800

PubMed: 31932756 ( click the link to review the publication )

Biology (Basel), 2020, 9(8):E218

PubMed: 32785105 ( click the link to review the publication )

ESMO Open, 2020, 5(4):e000707

PubMed: 32817058 ( click the link to review the publication )

Neoplasia, 2020, 22(9):376-389

PubMed: 32629178 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3946

PubMed: 32770055 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):387-402

PubMed: 32142667 ( click the link to review the publication )

Acta Neuropathol Commun, 2020, 8(1):139

PubMed: 32811569 ( click the link to review the publication )

Mol Cell, 2019, 76(6):872-884

PubMed: 31606273 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2197

PubMed: 31097693 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5143

PubMed: 31723142 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(21):6429-6442

PubMed: 31439581 ( click the link to review the publication )

Cancer Res, 2019,

PubMed: 31362929 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 29(3):573-588

PubMed: 31618628 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0298-5

PubMed: 30742091 ( click the link to review the publication )

Eur J Cancer, 2019, 109:137-153

PubMed: 30721788 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):272

PubMed: 31227006 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):56

PubMed: 30728057 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )
Cancers (Basel), 2019, 11(9)

PubMed: 31533235 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12824

PubMed: 31518489 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):128

PubMed: 31391125 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):119

PubMed: 31345255 ( click the link to review the publication )

ACS Chem Biol, 2019, 10.1021/acschembio-00191

PubMed: 31243962 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113616

PubMed: 31445021 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1225

PubMed: 30718660 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:223

PubMed: 31467489 ( click the link to review the publication )

Surgery, 2019, 10.1016/j.surg.2019.04.076

PubMed: 31585718 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Metabolites, 2019, 9(11)

PubMed: 31744229 ( click the link to review the publication )

Chembiochem, 2019, 10.1002/cbic.201900266

PubMed: 31152574 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0217399

PubMed: 31158244 ( click the link to review the publication )

Photodermatol Photoimmunol Photomed, 2019, 10.1111/phpp.12520

PubMed: 31618797 ( click the link to review the publication )

Reprod Domest Anim, 2019, 54(5):741-749

PubMed: 30785650 ( click the link to review the publication )

Target Oncol, 2019, 14(5):619-626

PubMed: 31502118 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav8463

PubMed: 31453322 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

Ann Biomed Eng, 2019, 10.1007/s10439-019-02269-2

PubMed: 31020445 ( click the link to review the publication )

Sci Rep, 2019, 9(1):10865

PubMed: 31350469 ( click the link to review the publication )

Exp Gerontol, 2019, 126:110691

PubMed: 31421186 ( click the link to review the publication )
Int J Mol Sci, 2019, 20(23)

PubMed: 31783660 ( click the link to review the publication )

Transl Oncol, 2019, 13(2):275-286

PubMed: 31874374 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Mol Cell, 2018, 69(6):923-937

PubMed: 29547721 ( click the link to review the publication )

Mol Cell, 2018, 70(5):920-935

PubMed: 29883609 ( click the link to review the publication )

Nat Protoc, 2018, 13(12):2827-2843

PubMed: 30382243 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2500

PubMed: 29950559 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1466

PubMed: 29654229 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(5):1090-1102

PubMed: 29196297 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(14):3377-3385

PubMed: 29650750 ( click the link to review the publication )

Cancer research, 2018, 78(2):542-557

PubMed: 29180473 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Breast Cancer Res, 2018, 20(1):9

PubMed: 29382358 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(2):175-184

PubMed: 29249695 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):84-95

PubMed: 29133617 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):806-813

PubMed: 29167314 ( click the link to review the publication )

Mol Oncol, 2018, 12(1):74-88

PubMed: 29112787 ( click the link to review the publication )

Neoplasia, 2018, 20(5):467-477

PubMed: 29605720 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(22):3974-3985

PubMed: 30137437 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9991

PubMed: 29968772 ( click the link to review the publication )

Front Pharmacol, 2018, 9:856

PubMed: 30154717 ( click the link to review the publication )
ACS Med Chem Lett, 2018, 9(12):1199-1204

PubMed: 30613326 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):355-361

PubMed: 29534162 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36503-36514

PubMed: 30559933 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):325

PubMed: 29487283 ( click the link to review the publication )

Oncotarget, 2018, 9(17):13324-13336

PubMed: 29568360 ( click the link to review the publication )

Small GTPases, 2018, 10.1080/21541248.2018.1446697

PubMed: 29634387 ( click the link to review the publication )

Sci Rep, 2018, 8(1):10724

PubMed: 30013176 ( click the link to review the publication )

NPJ Syst Biol Appl, 2018, 4:39

PubMed: 30416750 ( click the link to review the publication )

Oncoimmunology, 2018, 8(1):e1512456

PubMed: 30546949 ( click the link to review the publication )

Cell Syst, 2018, 7(2):161-179

PubMed: 30007540 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28294-28308

PubMed: 29983861 ( click the link to review the publication )

Neural Regen Res, 2018, 13(2):252-256

PubMed: 29557374 ( click the link to review the publication )

Nat Commun, 2017, 8:15623

PubMed: 28585535 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4684-4696

PubMed: 28652244 ( click the link to review the publication )

Cell Mol Life Sci, 2017, 74(19):3631-3645

PubMed: 28551825 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15523

PubMed: 29138474 ( click the link to review the publication )

Anal Bioanal Chem, 2017, 409(15):3749-3756

PubMed: 28429064 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2741-2751

PubMed: 29048639 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68208-68220

PubMed: 28978109 ( click the link to review the publication )
Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(11 Pt B):2980-2992

PubMed: 28408301 ( click the link to review the publication )

Cell Death Differ, 2017, 24(1):83-97

PubMed: 27834956 ( click the link to review the publication )

Genome Res, 2017, 27(4):613-625

PubMed: 28179366 ( click the link to review the publication )

Oncogene, 2017, 36(27):3842-3851

PubMed: 28263969 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28350298 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(29):E5930-E5939

PubMed: 28684402 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(10)

PubMed: 29064427 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8206-8222

PubMed: 29492189 ( click the link to review the publication )

Blood Adv, 2017, 30;1(24):2147-2160

PubMed: 29296862 ( click the link to review the publication )

Nat Commun, 2016, 7:10274

PubMed: 26817517 ( click the link to review the publication )

Autophagy, 2016, 12(10):1776-1790

PubMed: 27464255 ( click the link to review the publication )

Leukemia, 2016, 30(4):937-46

PubMed: 26582644 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

J Biol Chem, 2016, 291(34):17804-15

PubMed: 27226552 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(7):778-84

PubMed: 26810603 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0152104

PubMed: 27015094 ( click the link to review the publication )

Oncotarget, 2016, 8(35):58021-58036

PubMed: 28938534 ( click the link to review the publication )

Oncotarget, 2016, 7(21):30453-60

PubMed: 27028853 ( click the link to review the publication )

Sci Rep, 2016, 6:23713

PubMed: 27025703 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27557444 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75839-75853

PubMed: 27713119 ( click the link to review the publication )

Oncotarget, 2016, 7(12):15065-92

PubMed: 26918341 ( click the link to review the publication )
Cell Res, 2015, 10.1038/cr.2015.56

PubMed: 25952668 ( click the link to review the publication )

Mol Ther, 2015, 23(5):931-942

PubMed: 25619724 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(8):2021-2030

PubMed: 25748555 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

J Immunother, 2015, 38(1):12-23

PubMed: 25415284 ( click the link to review the publication )

Eur J Pharmacol, 2015, 762:283-92

PubMed: 26048310 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Cancer Res, 2015, 75(1):216-29

PubMed: 25381152 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(12):1934-7

PubMed: 26443648 ( click the link to review the publication )

Oncotarget, 2015, 6(38):40535-56

PubMed: 26497853 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(6):602-9

PubMed: 25795007 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2700-11

PubMed: 26351322 ( click the link to review the publication )

J Clin Invest, 2014, 124(3):1406-17

PubMed: 24569374 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):5074-84

PubMed: 25329694 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )

Transl Res, 2014, 164(5):411-23

PubMed: 25016932 ( click the link to review the publication )

The University of Texas, 2014, Lizee S

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Targets

B-Raf (V600E) ^[3] (Cell-free assay)	B-Raf ^[3] (Cell-free assay)	C-Raf ^[3] (Cell-free assay)
0.7 nM	5.2 nM	6.3 nM

In vitro

Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-Raf^V600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-Raf^V600E. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
	MVzLbY5ie2ViQYPzZZk>				MkH1TY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFjpd{B1[WepZXSgRk1T[WZiVk[wNGUhdXW2YX70JIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDpcpNm[3RiY3XscJMh[29vZYjwdoV{e2mwZzDDSGM{PyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBjcW:2aX75cIF1\WRvTVXLJJBzd3SnaX6gdIhwe3Cqb4L5cIF1cW:wIHL5JGFteGijU3Py[YVvKGG\|c3H5JJdqfGhiSVO1NEBw\iByLkCwNFch\|ryP	M3ixWFI1QTByNkez
SK-MEL-28	MWfLbY5ie2ViQYPzZZk>		M{XoZ\|EhcA>?		MXzJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfCCrbjDoeY1idiCVSz3NSWwuOjhiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gSXJMKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFQh\|ryP	MWmyOFkxODZ5Mx?=
HepG2	M{XPWGtqdmG\|ZTDBd5NigQ>?				M1q4T2lvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62IHnuJIh2dWGwIFjldGczKGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIFXST{BxcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEC0JO69VQ>?	NELJWWszPDlyME[3Ny=>
COLO205	NGjaWIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPofo5KdmirYnn0bY9vKG:oIHj1cYFvKEORTF:yNFUh[2WubDDwdo9tcW[ncnH0bY9vKHerdHigTWM2OCCxZjCwMlAxPyEQvF2=	NWTWbIVjOjR7MEC2O\|M>
HepG2	NFnPU2RHfW6ldHnvckBCe3OjeR?=		MYG0OUBucW5?	M13n[WROW09?	NFvkRYdKdmirYnn0bY9vKG:oIFHsb\|UhcW5iVFfGMYJmfGFvc4TpcZVt[XSnZDDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCVbXHkNkBxcG:\|cHjvdplt[XSrb36geJJm[XSnZDDmc5IhPDVibXnud{BxemmxcjD0c{BVT0ZvYnX0ZUB{fGmvdXzheIlwdiCvZXHzeZJm\CCjZoTldkA3OCCvaX7zJIJ6KG:meYPz[Zkh[myxdDDzZ4FvdmW{IHHuZYx6e2m\|IIfpeIghUUN3MDDv[kA{NjdizszN	NFH4[\|gzPDlyME[3Ny=>
HFF	NILSVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWSxNEDPxE1?	MmrJO\|IhcA>?	MWDEUXNQ	NGLqVIlKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44hd2ZiaIXtZY4hUE[IIHPlcIx{KGijcnLvdolv\yC5aXzkJJR6eGViQj3SZYYhf2m2aDDJR\|UxKG:oIEOg{txO	M4Pi[VI{QDR2MEO4
SK-MEL-28	M17Ycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{j5blExKM7:TR?=	NUnqS3FYPzJiaB?=	M1vqW2ROW09?	MmnOTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRvZILpeoVvKFONLV3FUE0zQCClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvODR\|IN88US=>	NXHnPJhlOjN6NESwN\|g>
A375P-F11	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NESwfWMyOCEQvF2=	M1jhT\|czKGh?	NWjMVY9tTE2VTx?=	NV7qW3hxUW6qaXLpeIlwdiCxZjDCMXJi\iCYNkCwSUBufXSjboSt[JJqfmWwIFGzO\|VRNUZzMTDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEexJO69VQ>?	NFvhdWkzOzh2NECzPC=>
MALME-3M	NGLreohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zGfVExKM7:TR?=	NIO1UFE4OiCq	M2HpfmROW09?	M3PFbmlEPTB;MTDuUS=>	MWeyN\|g1PDB\|OB?=
UACC-62	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU[xNEDPxE1?	MlrtO\|IhcA>?	M2m3c2ROW09?	NWnaTWo{UUN3ME2xJI5O	MVqyN\|g1PDB\|OB?=
C32TG	M1PsPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLn[4NDOTBizszN	MWK3NkBp	MYPEUXNQ	MWXJR\|UxRTFibl2=	MVOyN\|g1PDB\|OB?=
SK-MEL-1	M2\nXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{m4[lExKM7:TR?=	NXfTcIdVPzJiaB?=	MYLEUXNQ	NYXRVmhWUUN3ME2yJI5O	NV;2S2V5OjN6NESwN\|g>
M14	NE\zRnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkS1NVAh\|ryP	MXq3NkBp	MUPEUXNQ	MVTJR\|UxRTJibl2=	MXuyN\|g1PDB\|OB?=
SK-MEL-28	MofCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnFTHF{OTBizszN	MWi3NkBp	NWTT[WFpTE2VTx?=	MWLJR\|UxRTNibl2=	NWPobVdqOjN6NESwN\|g>
A375	NFXDbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYmxNEDPxE1?	NV7OVYE5PzJiaB?=	NX;vVZE3TE2VTx?=	NWHDOJlxUUN3ME20JI5O	M13NfFI{QDR2MEO4
DU-4475	NEnjcpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnKT4UyOCEQvF2=	MoHPO\|IhcA>?	MWHEUXNQ	M{LtcGlEPTB;NTDuUS=>	MYiyN\|g1PDB\|OB?=
UACC-257	NHvTTWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLOUYgyOCEQvF2=	NH6ycWE4OiCq	NGPscpFFVVOR	MnPvTWM2OD14IH7N	NWL4RocxOjN6NESwN\|g>
Colo 205	NF;yPWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUWxNEDPxE1?	M4DoelczKGh?	NUHK[Jc1TE2VTx?=	M2XCfWlEPTB;NzDuUS=>	M2PBVFI{QDR2MEO4
SK-MEL-3	MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfKR2x1OTBizszN	M4LwOlczKGh?	MUXEUXNQ	NWT0e4U3UUN3ME23JI5O	M{nr[\|I{QDR2MEO4
SH-4	MmLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUmxNEDPxE1?	MmXiO\|IhcA>?	M4jGOGROW09?	MWXJR\|UxRThibl2=	M13UclI{QDR2MEO4
A101D	NH7I[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoP3NVAh\|ryP	NE\t[IM4OiCq	M2m1OGROW09?	M4W5NWlEPTB;OTDuUS=>	MUCyN\|g1PDB\|OB?=
ES-2	MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1y3XVExKM7:TR?=	M3\RUlczKGh?	M2rQcmROW09?	MmG3TWM2OD13MzDuUS=>	NUTlO\|B1OjN6NESwN\|g>
HT-29	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW[xNEDPxE1?	MoPuO\|IhcA>?	NIrHNlVFVVOR	NHvldmdKSzVyPU[2JI5O	MneyNlM5PDRyM{i=
SW1417	M1zYbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DuTlExKM7:TR?=	NYnN[GVkPzJiaB?=	NG\RNplFVVOR	MVjJR\|UxRTF3ODDuUS=>	NV62UGlSOjN6NESwN\|g>
SW872	NHrwSJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXCNVAh\|ryP	NHrRV2Q4OiCq	M3X2OGROW09?	NH7rO45KSzVyPUO3O{BvVQ>?	NVfROlE3OjN6NESwN\|g>
RKO	NWT6fYROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLVNVAh\|ryP	NWmxZ4xQPzJiaB?=	MonuSG1UVw>?	M2PJVGlEPTB;Mj61NlIh\|ryP	NIT1dFMzOzh2NECzPC=>
A673	M2OwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUixNEDPxE1?	MU[3NkBp	MlHNSG1UVw>?	MWHJR\|UxRTFyIN88US=>	NGHjZ5AzOzh2NECzPC=>
GCT	MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnSdJZMOTBizszN	NH[3d5Q4OiCq	MVLEUXNQ	NFPSVYFKSzVyPUGwJO69VQ>?	NWPoW3Z2OjN6NESwN\|g>
WM-115	NWHBeW96T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYixNEDPxE1?	NHG1SnU4OiCq	NE\Ie4pFVVOR	NWDkRWZLUUN3ME21JI5O	MWmyN\|g1PDB\|OB?=
YUMAC	M4nKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXK4NlhbOTBizszN	NITidZE4OiCq	NFT2Xm5FVVOR	Mn;uTWM2OD13IH7N	NF;LVlgzOzh2NECzPC=>
OV-90	MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\JbFExKM7:TR?=	NIDneok4OiCq	MUfEUXNQ	MlfTTWM2OD1{OTDuUS=>	NUPNcYxrOjN6NESwN\|g>
NCI-H508	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37vSlExKM7:TR?=	NILVRZY4OiCq	NF3mRopFVVOR	NVXhZ4RkUUN3ME2xNEDPxE1?	MUSyN\|g1PDB\|OB?=
MDA-MB-231	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzFSGp{OTBizszN	NWnPdWxnPzJiaB?=	NITzRWRFVVOR	NV7idnVnUUN3ME2xNEDPxE1?	NULqfZJ3OjN6NESwN\|g>
SW756	Mki1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX:xNEDPxE1?	MUi3NkBp	MUjEUXNQ	NX;4Tpo1UUN3ME2xNEDPxE1?	NHLEeFQzOzh2NECzPC=>
SW-837	M2TXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HaRVExKM7:TR?=	MoPFO\|IhcA>?	MljqSG1UVw>?	NGXnbYNKSzVyPUGwJO69VQ>?	MUOyN\|g1PDB\|OB?=
UMUC-3	NWj1O45nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnBZWcyOCEQvF2=	MoHFO\|IhcA>?	NFLBVWtFVVOR	MYnJR\|UxRTFyIN88US=>	M4PHWFI{QDR2MEO4
LS-174T	NF7QdGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV[xNEDPxE1?	Ml\zO\|IhcA>?	Mme5SG1UVw>?	NGnSSmNKSzVyPUGwJO69VQ>?	MX[yN\|g1PDB\|OB?=
A549	NVfQW4lXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWCxNEDPxE1?	NWS2PZMzPzJiaB?=	MoizSG1UVw>?	NWDGV2NzUUN3ME2xNEDPxE1?	M13EWVI{QDR2MEO4
SHP-77	MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFf2e3oyOCEQvF2=	MYi3NkBp	Ml\4SG1UVw>?	NYfIfpl2UUN3ME2xNEDPxE1?	MXSyN\|g1PDB\|OB?=
SW480	NEXoXoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYixNEDPxE1?	MmTyO\|IhcA>?	NH3aNYZFVVOR	NIjJfXFKSzVyPUGwJO69VQ>?	MVWyN\|g1PDB\|OB?=
DLD-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\qeWYyOCEQvF2=	M4[wbFczKGh?	NV\WdIxVTE2VTx?=	NVPRT4lOUUN3ME2xNEDPxE1?	MVyyN\|g1PDB\|OB?=
HCT-116	MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzobmoyOCEQvF2=	MYK3NkBp	MUnEUXNQ	M{HUOGlEPTB;MUCg{txO	MYCyN\|g1PDB\|OB?=
NCI-H747	NHj6Z5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17m[FExKM7:TR?=	NFLOVJc4OiCq	NWLnZZVpTE2VTx?=	Mlv2TWM2OD1zMDFOwG0>	M2fFSVI{QDR2MEO4
T-84	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVKxNEDPxE1?	M2HjZVczKGh?	M3;xNWROW09?	MkDkTWM2OD1zMDFOwG0>	Mn;yNlM5PDRyM{i=
NCI-H460	NIjNZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV74RphSOTBizszN	M13YT\|czKGh?	Ml7aSG1UVw>?	MmLVTWM2OD1zMDFOwG0>	MWqyN\|g1PDB\|OB?=
Calu-6	MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\jXFJXOTBizszN	M1HDWVczKGh?	MYnEUXNQ	MYnJR\|UxRTFyIN88US=>	NFzXcFMzOzh2NECzPC=>
HCC-2998	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWCxNEDPxE1?	M1XJc\|czKGh?	NGj2UXJFVVOR	MUHJR\|UxRTFyIN88US=>	M{\HWlI{QDR2MEO4
LS1034	NFrVdo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\aOHgyOCEQvF2=	MYq3NkBp	NInr[m5FVVOR	NYq1b5JsUUN3ME2xNEDPxE1?	Mkn6NlM5PDRyM{i=
CHP-212	NVrCS\|V4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUexNEDPxE1?	M4nSTFczKGh?	NI\S[WlFVVOR	NYPoSoFEUUN3ME2xNEDPxE1?	NV35fXpSOjN6NESwN\|g>
SK-N-AS	M4XTRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnT4NVAh\|ryP	MYS3NkBp	M4CyUGROW09?	MVvJR\|UxRTFyIN88US=>	NWfYUINPOjN6NESwN\|g>
BFTC-905	NF\RRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrlNVAh\|ryP	MnLsO\|IhcA>?	NWrrXXhLTE2VTx?=	NIrPb25KSzVyPUGwJO69VQ>?	MlzINlM5PDRyM{i=
HuT78	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHBSHkyOCEQvF2=	MoXaO\|IhcA>?	M{TZVGROW09?	NHnVfFJKSzVyPUWyJI5O	MYCyN\|g1PDB\|OB?=
RPMI-8226	M4\adGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnyUGQyOCEQvF2=	MXG3NkBp	NH33VYdFVVOR	NX2w[YxUUUN3ME2yOlMhdk1?	NUTwenJpOjN6NESwN\|g>
BC-3	MkDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUWxNEDPxE1?	M4DpUVczKGh?	MVjEUXNQ	NFjDT2FKSzVyPUK3O{BvVQ>?	MYiyN\|g1PDB\|OB?=
ACHN	NX;WV452T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfoNVAh\|ryP	MX63NkBp	M4fISGROW09?	NUfnR2wyUUN3ME2yPVQhdk1?	M4LRVVI{QDR2MEO4
JRT3-T35	M4iyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWS0NVFIOTBizszN	MUe3NkBp	NWG1UJhuTE2VTx?=	NIfwWFZKSzVyPUK5OUBvVQ>?	NXW4[nBrOjN6NESwN\|g>
SK-MES-1	MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVr2PGU3OTBizszN	NYftVIg6PzJiaB?=	MWjEUXNQ	M3K0W2lEPTB;M{K5JI5O	MlLCNlM5PDRyM{i=
CESS	M4rEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjmZWRuOTBizszN	Mo\pO\|IhcA>?	NUTRbFdPTE2VTx?=	NFPMNpJKSzVyPUS5O{BvVQ>?	MoPnNlM5PDRyM{i=
H4	M1fKOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4DxVlExKM7:TR?=	MmfHO\|IhcA>?	MV7EUXNQ	Mke4TWM2OD14MUmgcm0>	MWOyN\|g1PDB\|OB?=
BC-1	M4fyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nIfFExKM7:TR?=	NYnKRVRYPzJiaB?=	MlPiSG1UVw>?	MmrvTWM2OD15MESgcm0>	M{HnV\|I{QDR2MEO4
DB	NUDKbG04T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3FNVAh\|ryP	MWK3NkBp	MYXEUXNQ	MX;JR\|UxRTh5MzDuUS=>	MojKNlM5PDRyM{i=
RPMI-6666	NFzjXJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYexNEDPxE1?	M4HiXVczKGh?	MnLhSG1UVw>?	M2DDdWlEPTB;OUK4JI5O	NIX0TnAzOzh2NECzPC=>
MC/CAR	M1fROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlizNVAh\|ryP	NULofJU6PzJiaB?=	Ml32SG1UVw>?	Ml3oTWM2OD1zLkCwNkDPxE1?	NHTmUZkzOzh2NECzPC=>
SNU-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHONVAh\|ryP	MnvRO\|IhcA>?	MoW3SG1UVw>?	NHfxRVBKSzVyPUGuOVAyKM7:TR?=	NXHaV25VOjN6NESwN\|g>
CEM/C1	NFHDbVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmm1NVAh\|ryP	NX\qPW1wPzJiaB?=	NXvvXHpUTE2VTx?=	M{fPVWlEPTB;MT63O\|Mh\|ryP	NVXlXVJzOjN6NESwN\|g>
GDM-1	NFSwV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3oNVAh\|ryP	MYS3NkBp	NVvN[5VMTE2VTx?=	NVjK[mxTUUN3ME2xMlk6PyEQvF2=	NXLa[ZpSOjN6NESwN\|g>
HT-1080	NGS1UIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYixNEDPxE1?	NGfzW3A4OiCq	NFL2d3pFVVOR	M3OycmlEPTB;Mj6wNFQh\|ryP	M4O3[lI{QDR2MEO4
HL-60	NUj5eVJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUixNEDPxE1?	NX7tTVltPzJiaB?=	NFvkVmVFVVOR	M2jTVmlEPTB;Mj6xO\|gh\|ryP	MnfSNlM5PDRyM{i=
C3A	NW\1XVJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH[xU5EyOCEQvF2=	NIflcJM4OiCq	M4LYTWROW09?	MXLJR\|UxRTVwNEG0JO69VQ>?	MmrlNlM5PDRyM{i=
MES-SA	NH;FS4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlr1NVAh\|ryP	NWPhSJdtPzJiaB?=	MVLEUXNQ	MWXJR\|UxRTZwOUi5JO69VQ>?	Mn;YNlM5PDRyM{i=
22Rv1	M2O0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4faUlExKM7:TR?=	NYLsSG9MPzJiaB?=	NFS1RVFFVVOR	NGfTTmtKSzVyPUGwJO69VQ>?	MlPGNlM5PDRyM{i=
647-V	M1XmbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPkN40yOCEQvF2=	MoTNO\|IhcA>?	MVLEUXNQ	MlnITWM2OD1zMDFOwG0>	NV7vSmpyOjN6NESwN\|g>
786-O	NYDsfXI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\ITmsyOTBizszN	MoDBO\|IhcA>?	M{TLXWROW09?	Mkn0TWM2OD1zMDFOwG0>	MUGyN\|g1PDB\|OB?=
A172	M3LmN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW[xNEDPxE1?	NVvUbFFmPzJiaB?=	NIH1[ZBFVVOR	NUHFN4J{UUN3ME2xNEDPxE1?	NV3vTnU{OjN6NESwN\|g>
A204	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3j1cFExKM7:TR?=	NGD2cVU4OiCq	NGrse\|NFVVOR	MlzSTWM2OD1zMDFOwG0>	M4SxOFI{QDR2MEO4
A427	NX65TGdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXW2SYY{OTBizszN	MXq3NkBp	MlnCSG1UVw>?	NH7PSHJKSzVyPUGwJO69VQ>?	NFvGXYczOzh2NECzPC=>
A431	MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYm2TFVvOTBizszN	MmX2O\|IhcA>?	NHrIV2FFVVOR	MYXJR\|UxRTFyIN88US=>	MnvUNlM5PDRyM{i=
A2780	NIDkWGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4ewbVExKM7:TR?=	NYrkZYhpPzJiaB?=	MYrEUXNQ	NID6VmFKSzVyPUGwJO69VQ>?	MlvKNlM5PDRyM{i=
ARH-77	M3:0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PJU\|ExKM7:TR?=	NGL0bHU4OiCq	NFS0RZdFVVOR	NUftXpJPUUN3ME2xNEDPxE1?	NXu5OJM5OjN6NESwN\|g>
Be(2)C	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rSNFExKM7:TR?=	M4jLVlczKGh?	MXrEUXNQ	NHPVNXpKSzVyPUGwJO69VQ>?	M1G3WVI{QDR2MEO4
BT-20	MlXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3K4bFExKM7:TR?=	NFiwTJc4OiCq	MnXkSG1UVw>?	MYLJR\|UxRTFyIN88US=>	NELFeZEzOzh2NECzPC=>
BxPc3	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vJU\|ExKM7:TR?=	NVmw[VBbPzJiaB?=	NUjVWIwxTE2VTx?=	NW\IPZRxUUN3ME2xNEDPxE1?	Moe2NlM5PDRyM{i=
C-4 I	NILTU\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HGSFExKM7:TR?=	NWewTZdiPzJiaB?=	MYLEUXNQ	Mnv5TWM2OD1zMDFOwG0>	NUXjOHZLOjN6NESwN\|g>
C33A	NULkPFJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrscmVOOTBizszN	MVi3NkBp	MlW4SG1UVw>?	NV3ZSndqUUN3ME2xNEDPxE1?	NHvvc5kzOzh2NECzPC=>
CAL-27	NW\jPFVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDQUlEyOCEQvF2=	MYi3NkBp	MUnEUXNQ	NHu3SYxKSzVyPUGwJO69VQ>?	NH;W[JYzOzh2NECzPC=>
CAL-62	NFL2Oo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jHNlExKM7:TR?=	M1HEeFczKGh?	MXPEUXNQ	M3PySWlEPTB;MUCg{txO	MUiyN\|g1PDB\|OB?=
Calu-3	NG\EdIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDDNVAh\|ryP	NH7BUoM4OiCq	NVmzcpdWTE2VTx?=	MoDRTWM2OD1zMDFOwG0>	NV[2RZk4OjN6NESwN\|g>
CaOV3	NHXXO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTmNVAh\|ryP	MUS3NkBp	NV;PdJJ{TE2VTx?=	M3i2S2lEPTB;MUCg{txO	M{HF[VI{QDR2MEO4
CGTHW1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWSxNEDPxE1?	NYm0W4pHPzJiaB?=	NGWxSoJFVVOR	MknoTWM2OD1zMDFOwG0>	NUO0d\|hEOjN6NESwN\|g>
CHL-1	MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfzOlIxOTBizszN	M{TEdVczKGh?	Mn20SG1UVw>?	M{fkcGlEPTB;MUCg{txO	MWeyN\|g1PDB\|OB?=
Colo320DM	NFHJOVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml[yNVAh\|ryP	NVvje4J1PzJiaB?=	MkjjSG1UVw>?	NVflZ2VUUUN3ME2xNEDPxE1?	MYWyN\|g1PDB\|OB?=
Colo704	Mn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DGZlExKM7:TR?=	MWK3NkBp	NWfCTpp7TE2VTx?=	MUTJR\|UxRTFyIN88US=>	MWqyN\|g1PDB\|OB?=
COR-L23	M{XLb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mny4NVAh\|ryP	NHfDW4o4OiCq	M3rxNGROW09?	NX3yWnVyUUN3ME2xNEDPxE1?	MXuyN\|g1PDB\|OB?=
CRO-AP2	M2TJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HuOlExKM7:TR?=	MnfhO\|IhcA>?	NF7zUlBFVVOR	NX\zUmV[UUN3ME2xNEDPxE1?	NYG5b4VPOjN6NESwN\|g>
Daudi	NG\V[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVqxNEDPxE1?	NF;nTHg4OiCq	NIDaSmhFVVOR	M4fXUWlEPTB;MUCg{txO	M2jjb\|I{QDR2MEO4
DOTC 24510	Mn7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnUeId5OTBizszN	NEfQSVU4OiCq	M3W3PWROW09?	Ml\PTWM2OD1zMDFOwG0>	M4\BS\|I{QDR2MEO4
DU-145	NYTWTpNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3kVXhXOTBizszN	M3jmd\|czKGh?	NUPyWGt7TE2VTx?=	MWHJR\|UxRTFyIN88US=>	NUL0[2JROjN6NESwN\|g>
EB-3	NUj4VHlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWmxNEDPxE1?	NWDnO4F5PzJiaB?=	NIDpOFNFVVOR	NULjZndbUUN3ME2xNEDPxE1?	M{HMZVI{QDR2MEO4
EFM-19	MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWWxNEDPxE1?	NGG2RlQ4OiCq	MXXEUXNQ	MV\JR\|UxRTFyIN88US=>	NYq0[GYxOjN6NESwN\|g>
EKVX	Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXWxNEDPxE1?	NEXzS\|k4OiCq	NEPGOYVFVVOR	MXHJR\|UxRTFyIN88US=>	NGTwbYgzOzh2NECzPC=>
FaDu	NFLFS5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\pblExKM7:TR?=	M3u3[lczKGh?	MXrEUXNQ	NVO5RYNQUUN3ME2xNEDPxE1?	MkjCNlM5PDRyM{i=
G401	Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWixNEDPxE1?	MlfLO\|IhcA>?	MkC5SG1UVw>?	NIrD[3VKSzVyPUGwJO69VQ>?	MXWyN\|g1PDB\|OB?=
HCC-70	NFnWWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13sdlExKM7:TR?=	NEDKXIk4OiCq	MXzEUXNQ	MlHyTWM2OD1zMDFOwG0>	NUi0c2lzOjN6NESwN\|g>
HCC-1954	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPZSGkyOCEQvF2=	MWC3NkBp	M1;lWWROW09?	M4jpemlEPTB;MUCg{txO	NHu4dm4zOzh2NECzPC=>
Hela	NFS0UWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{T6N\|ExKM7:TR?=	MoP3O\|IhcA>?	MmfqSG1UVw>?	NF\sO5FKSzVyPUGwJO69VQ>?	MmrDNlM5PDRyM{i=
Hep3B	MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XHXVExKM7:TR?=	MnnPO\|IhcA>?	NWLXW4dQTE2VTx?=	NHPk[3BKSzVyPUGwJO69VQ>?	MnzQNlM5PDRyM{i=
HMCB	NHzPZZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;oNVAh\|ryP	NIHQb5U4OiCq	MWTEUXNQ	MV7JR\|UxRTFyIN88US=>	MnTkNlM5PDRyM{i=
HN5	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDmS\|NHOTBizszN	MlrzO\|IhcA>?	M1jGT2ROW09?	M3i4[WlEPTB;MUCg{txO	Mn;PNlM5PDRyM{i=
HOS	Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{P0NVExKM7:TR?=	M13mTlczKGh?	M1q2fGROW09?	MXTJR\|UxRTFyIN88US=>	NVSwUFVOOjN6NESwN\|g>
HPAF-II	NWH1e4dDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmH6NVAh\|ryP	NVXodmlnPzJiaB?=	MkO5SG1UVw>?	MX\JR\|UxRTFyIN88US=>	MUSyN\|g1PDB\|OB?=
Hs746.T	NXvKN2xsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY[xNEDPxE1?	MWO3NkBp	MVHEUXNQ	Ml;rTWM2OD1zMDFOwG0>	M{H3e\|I{QDR2MEO4
HT	NIHh[YdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmCwNVAh\|ryP	MkTkO\|IhcA>?	MWXEUXNQ	MnO1TWM2OD1zMDFOwG0>	NGn2NoczOzh2NECzPC=>
HT-3	NVnZN2k2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkX5NVAh\|ryP	NX36RYl{PzJiaB?=	MUXEUXNQ	NGX4WIJKSzVyPUGwJO69VQ>?	NYqxSGsxOjN6NESwN\|g>
HuNS-1	M{LLcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3PfnhEOTBizszN	MlTlO\|IhcA>?	NXrUUGVtTE2VTx?=	M{DU[mlEPTB;MUCg{txO	MXWyN\|g1PDB\|OB?=
IGROV1	Mn33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7yNVAh\|ryP	NFyxbnk4OiCq	NGHINm9FVVOR	NWLI[Zk5UUN3ME2xNEDPxE1?	NGLje\|EzOzh2NECzPC=>
J82	MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\CNlExKM7:TR?=	MUi3NkBp	MXzEUXNQ	Mm\pTWM2OD1zMDFOwG0>	Mn\ONlM5PDRyM{i=
JM1	NXuxRpNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjHcnMyOCEQvF2=	MXK3NkBp	MlT2SG1UVw>?	NX\LfW5DUUN3ME2xNEDPxE1?	NHflO2czOzh2NECzPC=>
Kato III	MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XCR\|ExKM7:TR?=	M1rXbFczKGh?	MoLoSG1UVw>?	NE\KTWlKSzVyPUGwJO69VQ>?	NEXhN\|czOzh2NECzPC=>
KHOS-240S	M3zMWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjJNVAh\|ryP	MlrpO\|IhcA>?	Mlq5SG1UVw>?	MnPhTWM2OD1zMDFOwG0>	NF2zUI4zOzh2NECzPC=>
KM-12	NGToOHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLFOYwyOCEQvF2=	MV[3NkBp	MUHEUXNQ	Ml21TWM2OD1zMDFOwG0>	NEfVVIYzOzh2NECzPC=>
KPL-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\CeVloOTBizszN	NXn5dog4PzJiaB?=	NVrXeGRMTE2VTx?=	M{D1U2lEPTB;MUCg{txO	M{TDUlI{QDR2MEO4
KYSE-30	NEHYbnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2D3VlExKM7:TR?=	NIrYO4M4OiCq	M{\EPWROW09?	M1;4bmlEPTB;MUCg{txO	MXeyN\|g1PDB\|OB?=
LNCaP	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELWcXIyOCEQvF2=	MV23NkBp	NV7CRolETE2VTx?=	MkGwTWM2OD1zMDFOwG0>	MWeyN\|g1PDB\|OB?=
MCF-7	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGL0N\|YyOCEQvF2=	MYO3NkBp	NFmzS\|VFVVOR	MUnJR\|UxRTFyIN88US=>	M4jm[\|I{QDR2MEO4
MC-IXC	NF7VXWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\4NVAh\|ryP	MWS3NkBp	NIK3XFJFVVOR	MWLJR\|UxRTFyIN88US=>	MnGxNlM5PDRyM{i=
MDA-MB-175 VII	NWXTRpdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TwfFExKM7:TR?=	NE[z[2s4OiCq	NFnJOZJFVVOR	MY\JR\|UxRTFyIN88US=>	NG\hc4gzOzh2NECzPC=>
MDA-MB-468	M37GOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjQVJIyOCEQvF2=	MYm3NkBp	NYrCVXhjTE2VTx?=	NXnqXmpVUUN3ME2xNEDPxE1?	NI\sWWYzOzh2NECzPC=>
MiaPaCa	NInOXnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHZNVAh\|ryP	M1zm[lczKGh?	MY\EUXNQ	Mor0TWM2OD1zMDFOwG0>	NFHPWpIzOzh2NECzPC=>
Molt-4	MkCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVGxNEDPxE1?	NVL6em9OPzJiaB?=	NVO0W4hDTE2VTx?=	NE\KfnNKSzVyPUGwJO69VQ>?	MV6yN\|g1PDB\|OB?=
NCI-ADR/RES	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLh[FNjOTBizszN	MXi3NkBp	NYnDb5YyTE2VTx?=	NX\XXVJSUUN3ME2xNEDPxE1?	M4CyU\|I{QDR2MEO4
NCI-H69	MoHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYqxNEDPxE1?	NYi2fIxnPzJiaB?=	M2LVXmROW09?	M33LU2lEPTB;MUCg{txO	MVSyN\|g1PDB\|OB?=
NCI-H82	M1rOU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHPeHEyOCEQvF2=	M{XYOVczKGh?	M2fOb2ROW09?	NXLjeGdVUUN3ME2xNEDPxE1?	MXGyN\|g1PDB\|OB?=
NCI-N87	NHT2e2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYCxNEDPxE1?	MnrGO\|IhcA>?	NVXmdlNsTE2VTx?=	NIfp[IpKSzVyPUGwJO69VQ>?	MXGyN\|g1PDB\|OB?=
NCI-H146	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEW4U2gyOCEQvF2=	MVe3NkBp	MVPEUXNQ	M3P3R2lEPTB;MUCg{txO	NF;yfoszOzh2NECzPC=>
NCI-H157	NHX1PGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEflV2QyOCEQvF2=	NFjxfmw4OiCq	MlXmSG1UVw>?	MkXETWM2OD1zMDFOwG0>	MoDQNlM5PDRyM{i=
NCI-H187	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HnXFExKM7:TR?=	NF\3S4M4OiCq	MU\EUXNQ	MYrJR\|UxRTFyIN88US=>	MYGyN\|g1PDB\|OB?=
NCI-H209	NWC3O5F4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWmxNEDPxE1?	NYLrdHRjPzJiaB?=	MnnsSG1UVw>?	M12xWWlEPTB;MUCg{txO	NHLQT5EzOzh2NECzPC=>
NCI-H226	M3n5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\zdVExKM7:TR?=	NIXtT2g4OiCq	M3;ocmROW09?	NHHneHBKSzVyPUGwJO69VQ>?	NF\0NpgzOzh2NECzPC=>
NCI-H292	NF7PPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX6xNEDPxE1?	MX23NkBp	Mly3SG1UVw>?	M4DDN2lEPTB;MUCg{txO	MYOyN\|g1PDB\|OB?=
NCI-H322	M{XpPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnPfW54OTBizszN	NWWxdpJmPzJiaB?=	NGK0PHFFVVOR	M1y3eGlEPTB;MUCg{txO	NV7mOodrOjN6NESwN\|g>
NCI-H358	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HpOVExKM7:TR?=	M{nQPFczKGh?	M1vpPWROW09?	NGXieW5KSzVyPUGwJO69VQ>?	MUOyN\|g1PDB\|OB?=
NCI-H520	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Lq[VExKM7:TR?=	MXy3NkBp	M3\1ZmROW09?	MVzJR\|UxRTFyIN88US=>	MorHNlM5PDRyM{i=
NCI-H526	NGK2XG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPKSolzOTBizszN	NH62UXM4OiCq	MnqwSG1UVw>?	NWHyR253UUN3ME2xNEDPxE1?	NHKyW24zOzh2NECzPC=>
NCI-H630	NIPYSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LId\|ExKM7:TR?=	NVe5[Jl{PzJiaB?=	NX;5OnRXTE2VTx?=	Ml;jTWM2OD1zMDFOwG0>	MWqyN\|g1PDB\|OB?=
NCI-H661	M3zmVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLjXocyOCEQvF2=	NFKzUHQ4OiCq	Ml[3SG1UVw>?	MmS5TWM2OD1zMDFOwG0>	MXGyN\|g1PDB\|OB?=
NCI-H716	NELlZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXj4NVRCOTBizszN	M{D5fVczKGh?	NVTRW\|M6TE2VTx?=	MYPJR\|UxRTFyIN88US=>	MVKyN\|g1PDB\|OB?=
NCI-H1563	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXNUm0yOCEQvF2=	NGnifJM4OiCq	MWjEUXNQ	M3jLUmlEPTB;MUCg{txO	MkHHNlM5PDRyM{i=
NCI-H1792	M1\ISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXr5RVI1OTBizszN	MYS3NkBp	NV22doxZTE2VTx?=	MV3JR\|UxRTFyIN88US=>	M{X3T\|I{QDR2MEO4
NCI-H2030	MoTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHOVVJmOTBizszN	NX7PclF6PzJiaB?=	Mk\JSG1UVw>?	MX3JR\|UxRTFyIN88US=>	M4nGUVI{QDR2MEO4
NCI-H2052	NWqydHp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXqRlgyOTBizszN	NIXLSYI4OiCq	NXrBfJR5TE2VTx?=	MYLJR\|UxRTFyIN88US=>	NYHXdpN[OjN6NESwN\|g>
NCI-H2122	NXXyRWVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrkNVAh\|ryP	MVe3NkBp	M3GzUGROW09?	Ml32TWM2OD1zMDFOwG0>	NW\uXIhEOjN6NESwN\|g>
NCI-H2228	MkWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4S4Z\|ExKM7:TR?=	NVHUV4g3PzJiaB?=	MYDEUXNQ	MX\JR\|UxRTFyIN88US=>	NVvqSphjOjN6NESwN\|g>
OE-19	NXmzd4tuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnESGtuOTBizszN	NXn0ZYFUPzJiaB?=	MlLMSG1UVw>?	NVziWYc2UUN3ME2xNEDPxE1?	NIPSRZYzOzh2NECzPC=>
OE-21	NYfSdGFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3oSZdLOTBizszN	MlzoO\|IhcA>?	MormSG1UVw>?	MVnJR\|UxRTFyIN88US=>	MXeyN\|g1PDB\|OB?=
OE-33	NGD6bWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWr3R3lzOTBizszN	MoHOO\|IhcA>?	M1\zNGROW09?	NGL3bW1KSzVyPUGwJO69VQ>?	NUe1Voh{OjN6NESwN\|g>
OVCAR-3	NH7oZoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\RNolOOTBizszN	MoPwO\|IhcA>?	MnnGSG1UVw>?	MmDNTWM2OD1zMDFOwG0>	M4\KWFI{QDR2MEO4
OVCAR-4	NUPQNWNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnCUFV6OTBizszN	NX;BWmZ[PzJiaB?=	MVrEUXNQ	MkDETWM2OD1zMDFOwG0>	Ml7hNlM5PDRyM{i=
OVCAR-5	NIfBWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HxblExKM7:TR?=	NH7aRXo4OiCq	NUPido8zTE2VTx?=	M1rFTGlEPTB;MUCg{txO	NWPybYdROjN6NESwN\|g>
P3HR-1	M4\NRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPpNVAh\|ryP	MYC3NkBp	MWPEUXNQ	M4LLdmlEPTB;MUCg{txO	M1HN[FI{QDR2MEO4
PC-3	NUn1WFkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrFNVAh\|ryP	MUW3NkBp	MVzEUXNQ	MXrJR\|UxRTFyIN88US=>	MYWyN\|g1PDB\|OB?=
Raji	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHpRnRyOTBizszN	NXLkTIJGPzJiaB?=	M4HNR2ROW09?	NGH5bo5KSzVyPUGwJO69VQ>?	MmjONlM5PDRyM{i=
RD	NHHYRoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXrcZEyOCEQvF2=	M1i0dlczKGh?	M{\wS2ROW09?	NYfQT5V4UUN3ME2xNEDPxE1?	M4jMeVI{QDR2MEO4
RD-ES	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnzXpY2OTBizszN	MYq3NkBp	MorqSG1UVw>?	MXjJR\|UxRTFyIN88US=>	MV[yN\|g1PDB\|OB?=
RL	MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYT6W4JTOTBizszN	MkfIO\|IhcA>?	NH\sN2RFVVOR	Ml7FTWM2OD1zMDFOwG0>	M2LVRVI{QDR2MEO4
SaOS2	M3vMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NESzR\|cyOCEQvF2=	M{jOdFczKGh?	M2TmWmROW09?	M4D4TmlEPTB;MUCg{txO	MVKyN\|g1PDB\|OB?=
SCC-9	M1TjUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUOxNEDPxE1?	NWT6cppKPzJiaB?=	MU\EUXNQ	MXzJR\|UxRTFyIN88US=>	M1fXWFI{QDR2MEO4
SCC-12	NULKZ3g6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVGxNEDPxE1?	MnjWO\|IhcA>?	M3HHbmROW09?	M4m2bGlEPTB;MUCg{txO	NGn1bHgzOzh2NECzPC=>
SCC-13	M{m1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rCSFExKM7:TR?=	MXi3NkBp	M4XQXGROW09?	MXXJR\|UxRTFyIN88US=>	MoHuNlM5PDRyM{i=
SCC-15	NFjlW2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\wOVExKM7:TR?=	NYK1NpE4PzJiaB?=	NXL2fFE1TE2VTx?=	NGLEdHNKSzVyPUGwJO69VQ>?	M1LpSVI{QDR2MEO4
SCC-25	M{PqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjoNVAh\|ryP	MVm3NkBp	M{DGbWROW09?	M{HOS2lEPTB;MUCg{txO	MVyyN\|g1PDB\|OB?=
SCLC-3	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLBWGIyOCEQvF2=	MmW4O\|IhcA>?	MnHHSG1UVw>?	MUHJR\|UxRTFyIN88US=>	M1zTR\|I{QDR2MEO4
SF-268	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17ZXFExKM7:TR?=	NUPnUYlSPzJiaB?=	MWLEUXNQ	MWXJR\|UxRTFyIN88US=>	MX[yN\|g1PDB\|OB?=
SF-295	NEnVfXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7BeopQOTBizszN	MYC3NkBp	MV;EUXNQ	NH\3d\|lKSzVyPUGwJO69VQ>?	NUixfmtnOjN6NESwN\|g>
SJRH30	NVrBbWd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHyNVAh\|ryP	NELrV2Q4OiCq	MYrEUXNQ	Mn;oTWM2OD1zMDFOwG0>	NGHaRlMzOzh2NECzPC=>
SK-BR-3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2L1PVExKM7:TR?=	MnT6O\|IhcA>?	NX;EfmlPTE2VTx?=	M1vuVmlEPTB;MUCg{txO	MVmyN\|g1PDB\|OB?=
SK-LMS-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3L2VFExKM7:TR?=	MlrSO\|IhcA>?	M3;1W2ROW09?	M1PUemlEPTB;MUCg{txO	MnnoNlM5PDRyM{i=
SK-N-DZ	NGTGNohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DacFExKM7:TR?=	MlraO\|IhcA>?	NF7vS5NFVVOR	M{noPWlEPTB;MUCg{txO	MmD5NlM5PDRyM{i=
SK-N-F1	NWHUNWROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfTUZg6OTBizszN	NEfOcGI4OiCq	NH2ybHZFVVOR	NFy2UZBKSzVyPUGwJO69VQ>?	Mon2NlM5PDRyM{i=
SKOV-3	M3vx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUexNEDPxE1?	M3niPFczKGh?	MkPNSG1UVw>?	Ml[yTWM2OD1zMDFOwG0>	NXTtVpc6OjN6NESwN\|g>
SK-UT-1	MmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUT1fI85OTBizszN	NYXKfW5XPzJiaB?=	M3XrNmROW09?	MV;JR\|UxRTFyIN88US=>	M4LmZ\|I{QDR2MEO4
SN12C	Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIj3NYMyOCEQvF2=	MmPTO\|IhcA>?	MV;EUXNQ	M4DkO2lEPTB;MUCg{txO	M1jCXVI{QDR2MEO4
SNB-19	Mn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFmwSJgyOCEQvF2=	NEn3bmY4OiCq	NEm3SFNFVVOR	M2nhTGlEPTB;MUCg{txO	MWeyN\|g1PDB\|OB?=
SNU-5	M37VSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHvNVAh\|ryP	NXjZZnIzPzJiaB?=	NWLHT5c2TE2VTx?=	NWC1NmRZUUN3ME2xNEDPxE1?	NGH3WI8zOzh2NECzPC=>
SNU-16	M2DOUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3f4SVExKM7:TR?=	NGPaS244OiCq	NV:x[JV{TE2VTx?=	NVTOcJRoUUN3ME2xNEDPxE1?	NHuxd4ozOzh2NECzPC=>
SNU-398	NEPie4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjGSWRlOTBizszN	M2jyRVczKGh?	NX\QRoE3TE2VTx?=	NWTDfFNmUUN3ME2xNEDPxE1?	MorZNlM5PDRyM{i=
SNU-449	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLRNVAh\|ryP	MnzFO\|IhcA>?	NInMfItFVVOR	M37ofGlEPTB;MUCg{txO	NYDhToV4OjN6NESwN\|g>
SR	M{DjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnYNVAh\|ryP	MlryO\|IhcA>?	MmfESG1UVw>?	MlHwTWM2OD1zMDFOwG0>	MmLHNlM5PDRyM{i=
ST486	MkH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVGxNEDPxE1?	MonVO\|IhcA>?	M1HlNGROW09?	NEX2TZdKSzVyPUGwJO69VQ>?	M2SwblI{QDR2MEO4
SW579	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zad\|ExKM7:TR?=	MWW3NkBp	NFj6XZpFVVOR	NHPKZW9KSzVyPUGwJO69VQ>?	NFzoZmozOzh2NECzPC=>
SW684	NXLHW5VuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LEUVExKM7:TR?=	MYm3NkBp	M1v0Z2ROW09?	M4rrVmlEPTB;MUCg{txO	MmnsNlM5PDRyM{i=
SW-780	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIL3V2syOCEQvF2=	MYi3NkBp	NVvOSJZjTE2VTx?=	MXHJR\|UxRTFyIN88US=>	MYSyN\|g1PDB\|OB?=
SW900	NWfqc4l4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInF[oEyOCEQvF2=	MojQO\|IhcA>?	MoWxSG1UVw>?	MlXUTWM2OD1zMDFOwG0>	MWSyN\|g1PDB\|OB?=
SW1088	NYr4e3pnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvyUotQOTBizszN	M4fWWlczKGh?	MnvxSG1UVw>?	M3juO2lEPTB;MUCg{txO	NUPq[nptOjN6NESwN\|g>
SW1463	NVr3cIdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1S1N\|ExKM7:TR?=	M4j6blczKGh?	MU\EUXNQ	Mo[3TWM2OD1zMDFOwG0>	NWfL[oJ[OjN6NESwN\|g>
SW1990	MnTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvSNVlnOTBizszN	NG\OTJg4OiCq	MkDFSG1UVw>?	MorjTWM2OD1zMDFOwG0>	NFrQ[FczOzh2NECzPC=>
T47D	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvaNVAh\|ryP	NIjXRmg4OiCq	M{XtZWROW09?	Mk\CTWM2OD1zMDFOwG0>	NVrQOFVnOjN6NESwN\|g>
TE381.T	MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWWxNEDPxE1?	MnfHO\|IhcA>?	M2TqVGROW09?	NH71eGNKSzVyPUGwJO69VQ>?	MmfwNlM5PDRyM{i=
TK-10	M4LKbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Xs[\|ExKM7:TR?=	NXPZb3RIPzJiaB?=	M{T4eWROW09?	NUPlW4VyUUN3ME2xNEDPxE1?	M{nVeVI{QDR2MEO4
U2OS	NVro[ZVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTCNlhxOTBizszN	Mkf2O\|IhcA>?	NYWxZpNmTE2VTx?=	Mo\4TWM2OD1zMDFOwG0>	MXGyN\|g1PDB\|OB?=
U251	MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETNWoIyOCEQvF2=	NFnWd\|A4OiCq	MmrmSG1UVw>?	NIPa[GVKSzVyPUGwJO69VQ>?	M1z2VlI{QDR2MEO4
UACC-812	NFLtcJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXq2PGZROTBizszN	M1joTlczKGh?	MX7EUXNQ	Ml\pTWM2OD1zMDFOwG0>	M1XUNFI{QDR2MEO4
YAPC	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX2xNEDPxE1?	M37OTVczKGh?	MWHEUXNQ	NXvke4lkUUN3ME2xNEDPxE1?	NYfI[5ROOjN6NESwN\|g>
ZR-75-1	NXvKSZFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\nNVAh\|ryP	MVy3NkBp	M1zldGROW09?	MV;JR\|UxRTFyIN88US=>	MVmyN\|g1PDB\|OB?=
A375	Mo\xSpVv[3Srb36gZZN{[Xl?	NVL0N3gzOS5{IN88US=>	MUS0JIg>	NVT2T3lUTE2VTx?=	MYHJcohq[mm2aX;uJI9nKHCqb4PwbI9zgWyjdHnvckBw\iCPRVusJGVTUyxiYX7kJHM3WA>?	MX2yNlM5QTR5MR?=
YUSIT1	M1rmUWZ2dmO2aX;uJIF{e2G7			NHj4dVRFVVOR	MkPzdoVlfWOnZDDz[Y5{cXSrdnn0fUB4cXSqIFnDOVAhRiByLkWg{txO	M1\1bFIzOzh7NEex
MeWo	NYrqU\|kzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M{LTXWROW09?	NWXUN3JEUUN3MDC9JFk5PyCwTR?=	M4PJOlI3ODF6NUK0
WiDr	MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NX7tNYNRTE2VTx?=	MnHaTWM2OCB;IEe2JI5O	MWKyOlAyQDV{NB?=
Colo-205	MX\GeY5kfGmxbjDhd5NigQ>?	NETT[mEyKM7:TR?=	Mme4OEBl	MmTuSG1UVw>?	NVzBOG5ZUW6mdXPl[EBiKGirZ3jsfUBkd22yYYLhZoxmKGOxbYDhZ5Rqd25icHjlco91gXCn	NVOyTIhvOjV\|OEGxOVI>
RBW-1	Mm\iSpVv[3Srb36gZZN{[Xl?	MUSxJO69VQ>?		MlHPSG1UVw>?	MnPZUo8hemWmdXP0bY9vKG:oIF3lb{AyNzJicHjvd5Bpd3K7bHH0bY9v	NIW1RmYzPDh6NU[5NC=>
RBO-1	M3ezfGZ2dmO2aX;uJIF{e2G7	NI\jSFUyKM7:TR?=		NGDZeWZFVVOR	M3fafGlvcGmkaYTpc44hd2ZiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44>	NUf5NWxIOjR6OEW2PVA>
RBO-2	M2T5TWZ2dmO2aX;uJIF{e2G7	MlHoNUDPxE1?		NEThSXNFVVOR	NUfRc5JtUW6qaXLpeIlwdiCxZjCgUYVsKDFxMjDwbI9{eGixconsZZRqd25?	M{X5VlI1QDh3Nkmw
RBOW	MnXwSpVv[3Srb36gZZN{[Xl?	NFTZOoUyKM7:TR?=		NFrnPVNFVVOR	MXjJcohq[mm2aX;uJI9nKCCPZXugNU8zKHCqb4PwbI9zgWyjdHnvci=>	M1GyNlI1QDh3Nkmw
M257	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELSdGgyODBibl2=	NVKw[YhuPzJiaB?=		NUHRZYxHTG:nczDuc5QhcW6qaXLpeEBxem:uaX\ldoF1cW:wIH;mJG0zPTdiY3XscEBp[XKkb4XybY5oKHerbHSgeJlx\SCEUlHG	NGPzclAzOzNzN{S0Oi=>
LCP	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXIU4QyODBibl2=	M1XwOVczKGh?		MofKTY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJI9nKEyFUDDj[YxtKGijcnLveZJqdmdiQmLBSkBXPjByUjDteZRidnSjdHnvci=>	NVjVXpNGOjN\|MUe0OFY>
WM266	M33IRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NESzWYgyODBibl2=	NV70SI1mPzJiaB?=		M1P0OGlvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckBw\iCZTUK2OkBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCxSEBufXSjboTheIlwdg>?	NELnS5IzOzNzN{S0Oi=>
M257	NYX0V\|dUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTQNVAxKG6P	NWm2[JB5PzJiaB?=		NYDZ[5Q6TG:nczDuc5QhcW6qaXLpeEBGWktzLUKgdIhwe3Cqb4L5cIF1cW:wIHnuJG0zPTdiY3XscEBp[XKkb4XybY5oKHerbHSgeJlx\SCEUlHG	NIj6cmYzOzNzN{S0Oi=>
LCP	Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PiTVExOCCwTR?=	NYXBPWZkPzJiaB?=		MojHTY5pcWKrdDDFVmsyNTJicHjvd5Bpd3K7bHH0bY9vKGmwIFzDVEBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCwVkBufXSjboTheIlwdg>?	NX;J[pRxOjN\|MUe0OFY>
WM266	Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHP[25WOTByIH7N	M1zVUFczKGh?		MlPuTY5pcWKrdDDFVmsyNTJicHjvd5Bpd3K7bHH0bY9vKGmwIGfNNlY3KGOnbHygbIFz[m:3cnnu[{BDWkGIIG[2NFBFKG23dHHueIF1cW:w	NGLoXJAzOzNzN{S0Oi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pMEK / pERK / ERK; PubMed: 31158244 PLoS One Cell lines as shown were treated with dabrafenib, over a dose range, for 1 hour. UT = untransfected. Expression and/or phosphorylation of the indicated proteins were assessed by immunoblot. p-S6 / p-AKT308 / p-AKT473; PubMed: 24735930 Mol Cancer Western blot analysis of phosphorylated proteins in MAPK and the PI3K-AKT pathway after 24 hours exposure to increasing concentrations of dabrafenib. β-catenin; PubMed: 29167314 Mol Cancer Ther HT-29 cells were treated with BRAF inhibitors Dabrafenib (2 μM), GDC-0879 (4 μM) or Vemurafenib (2 μM) for indicated times. The whole cell lysates were used for western blot with indicated antibodies.	31158244 24735930 29167314
Growth inhibition assay	IC50; PubMed: 24735930 Mol Cancer A panel of 23 BRAF(V600) mutant human melanoma cell lines was treated with serial dilutions (1-10,000 nM) of dabrafenib (A) for 72-120 hours to assess cell viability. The bars represent the average IC50 value of two or more independent experiments in duplicates and the error bars represent the SEM.	24735930

In vivo

Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. ^[1]

Protocol

References

Solubility (25°C)

In vitro	DMSO	30 mg/mL (57.74 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+45% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dabrafenib (GSK2118436) SDF

Molecular Weight	519.56
Formula	C₂₃H₂₀F₃N₅O₂S₂
CAS No.	1195765-45-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04452877	Not yet recruiting	Drug: Dabrafenib\|Drug: Trametinib	Carcinoma Non-Small-Cell Lung	Novartis Pharmaceuticals\|Novartis	August 31 2020	Phase 2
NCT04059224	Recruiting	Drug: Trametinib\|Drug: Dabrafenib	Stage IV Melanoma\|Stage III Melanoma	Universitair Ziekenhuis Brussel	January 28 2019	Phase 2
NCT03668431	Recruiting	Drug: Dabrafenib\|Drug: Trametinib\|Drug: PDR001	Metastatic Colorectal Cancer	Massachusetts General Hospital\|Novartis\|Stand Up To Cancer	October 15 2018	Phase 2
NCT03553329	Completed	Drug: dabrafenib	Unresecable Stage IIIc or IV Melanoma	Poitiers University Hospital	June 2 2018	--
NCT03593993	Recruiting	Procedure: Surgical Cohort	Glioma\|BRAF V600E\|Pleomorphic Xantho-Astrocytoma\|Glioblastoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Musella Foundation	May 19 2018	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Pan Raf Inhibitor

AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.
FDA-approved Raf Inhibitor

Sorafenib Tosylate : Approved by FDA for advanced renal cancer。
Newest Raf Inhibitor

TAK-632 ^New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

Related Raf Products

LY3009120 ^New

LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. LY03009120 induces autophagy. Phase 1.
Ravoxertinib (GDC-0994) ^New

Ravoxertinib (GDC-0994) is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
Ulixertinib (BVD-523) ^New

Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.
Vemurafenib (PLX4032)

Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-Raf^V600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-Raf^V600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold. Vemurafenib (PLX4032, RG7204) induces autophagy.

Features:A novel and potent inhibitor of the B-RAF^V600E oncoprotein.
Sorafenib

Sorafenib (BAY 43-9006) is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
Sorafenib Tosylate

Sorafenib Tosylate (Bay 43-9006) is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib Tosylate inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib Tosylate induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
PLX-4720

PLX4720 is a potent and selective inhibitor of B-Raf^V600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.
TAK-632

TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.
GDC-0879

GDC-0879 (AR-00341677) is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases.
GW5074

GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted. GW5074 inhibits LK-induced apoptosis.

Choose Your Country or Region

By Signaling Pathways

By product type

Dabrafenib (GSK2118436)